QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=E7D35A6E3B0228E522E16E817F38A117;jsessionid=04528176E75EF7623897F39CAEF4D5C1;jsessionid=FCF1B4EE87F618C33E0081E353FA5BC2 (gene)

1. ATXN2 is a target of N-terminal proteolysis.
2. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
3. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
4. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
5. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=E7D35A6E3B0228E522E16E817F38A117;jsessionid=04528176E75EF7623897F39CAEF4D5C1;jsessionid=FCF1B4EE87F618C33E0081E353FA5BC2